Leader Talks

Pharmaceutical Plant Design for SMEs: Balancing Long-Term Flexibility, Investment and GMP Readiness

Designing a pharmaceutical manufacturing facility is not just about meeting today’s production requirements; it is about building the flexibility to accommodate future growth without compromising operational efficiency or GMP compliance.

For SMEs, balancing capital investment, evolving product portfolios and regulatory requirements makes plant design a critical long-term decision. In this interaction with Hello Pharma, Mr. Rajesh Hedaoo, Managing Director, Gusto Total Solutions Pvt. Ltd., draws on over four decades of industry experience to share practical insights on plant design, engineering integration, manufacturing flexibility and GMP readiness.

Q1. How Can SMEs Design Future-Ready Pharmaceutical Manufacturing Plants Without Costly Modifications?

For pharmaceutical SMEs, future-ready plant design begins with understanding the products they intend to manufacture today and those they may introduce over the next 5–10 years.

This requires evaluating manufacturing technologies, unit operations, utility requirements, process hazards, chemical compatibility, raw material availability, import dependencies and future capacity needs. Automation requirements should also be assessed early, distinguishing between systems essential from the outset and those that can be introduced in phases.

The facility should accommodate current production while allowing capacity expansion and the introduction of products involving compatible processes. Provisions for future utilities, storage and supporting infrastructure must therefore be incorporated into the initial design.

Energy efficiency and a phased investment strategy are equally important. SMEs must balance capital expenditure (CAPEX) and operating expenditure (OPEX), allowing revenue from operations to support subsequent expansion. Throughout, the facility must comply with current Good Manufacturing Practices (cGMP) and sound engineering principles.

An Example from My Experience

In Dahej, Gujarat, we developed a master plan for a 40-acre manufacturing site accommodating four plants. The first facility was planned under Phase 1, with the remaining development distributed across two to three phases over 2–5 years.

The layout considered land contours, soil conditions, material movement and operational requirements. Manufacturing blocks, utilities, warehouses, tank farms, quality control facilities and supporting infrastructure were strategically positioned. Energy-efficient systems, instrumentation and automation were incorporated to support safe multiproduct manufacturing and operating-cost efficiency.

Importantly, future expansion was planned without disrupting existing operations. The first plant has since been successfully commissioned and handles multiple products, including processes involving ethoxylation reactions.

The key lesson is that expansion requirements must be addressed during initial master planning, not after the first plant becomes operational.

Q2. How can manufacturers balance capital investment, operational flexibility and future expansion when deciding between multipurpose facilities and dedicated production areas?

The choice between dedicated and multipurpose facilities should be based on the product portfolio, market demand, manufacturing requirements and long-term business objectives.

Continuous, high-volume manufacturing or products requiring specific containment arrangements may justify dedicated facilities. Lower-volume, higher-value products manufactured through periodic campaigns may be better suited to multipurpose facilities.

Multipurpose manufacturing offers operational flexibility but requires careful evaluation of cleaning validation, cross-contamination risks, equipment utilisation and product changeover costs.

A risk-based approach is particularly important when dealing with products that require specific containment or segregation measures. Depending on their characteristics and manufacturing risks, dedicated facilities or appropriately designed containment arrangements may be necessary.

The investment decision must balance CAPEX, operating costs, capacity utilisation, regulatory compliance and future expansion requirements.

An Example from My Experience

At Tarapur MIDC, Maharashtra, we developed a site master plan integrating dedicated production areas with a multipurpose manufacturing facility.

The client intended to manufacture two products in dedicated areas, using appropriately selected reactors, associated equipment and solvent recovery systems to support high-volume production. Other products were allocated to the multipurpose facility.

The design considered product portfolios, chemical reactions, present and future capacities, raw material compatibility, utility requirements, solvent recovery, recycling opportunities, effluents and gaseous emissions.

The resulting layout accommodated both manufacturing approaches without operational interference. CAPEX and operating overhead calculations were also undertaken, targeting a return on investment within four years.

The principle is to invest in dedicated capacity where process requirements justify it while retaining multipurpose capabilities wherever operationally feasible.

Q3. From process design to utilities, piping and automation, which engineering gaps most often cause project delays or operational problems, and how can they be identified before construction begins?

Engineering gaps often emerge at the interfaces between disciplines rather than within individual engineering functions. Process engineering, mechanical and piping systems, utilities, electrical engineering, instrumentation and automation must therefore be coordinated as an integrated system.

A multidisciplinary team should be involved from the conceptual stage. The design basis must capture process requirements, capacity calculations, equipment specifications, peak utility demands and the intended automation philosophy.

Front-end engineering reviews and 3D modelling of piping, cabling and HVAC systems help identify physical clashes, accessibility constraints and equipment placement issues before construction.

Disciplined project management is equally important. Regular interdisciplinary reviews, documented decisions and strict drawing revision control help prevent inconsistencies during execution. HAZOP studies and risk assessments should also be undertaken at appropriate engineering stages, alongside independent mechanical integrity and procurement quality checks.

An Example from My Experience

During an earlier pharmaceutical manufacturing project, deficiencies in piping material quality and construction-stage verification resulted in extensive rework of an automated solvent transfer system.

The corrective work involved replacing the affected piping, verifying material quality through appropriate certification and independent laboratory testing, and completing the necessary inspection, testing and validation activities. The system was subsequently commissioned successfully.

The experience reinforced four critical requirements: engineering specifications must be application-specific; material certifications and traceability must be verified before installation; HAZOP must be supplemented by mechanical integrity assessments; and piping sections should undergo progressive inspection and testing during construction wherever technically appropriate. Final testing of the completed system remains essential to verify installation integrity in accordance with applicable engineering codes and specifications.

Engineering responsibility does not end with an approved design. It must extend through procurement, construction, testing and commissioning, with quality and process safety taking precedence over cost reduction.

Q4. What engineering and validation requirements must be addressed during plant design to ensure GMP readiness and avoid delays between construction completion and commercial manufacturing?

GMP readiness must be built into the project from the design stage rather than treated as a separate activity towards completion.

A Validation Master Plan (VMP) should be developed during early engineering, defining the qualification strategy, responsibilities, documentation, deliverables and acceptance criteria for commissioning, qualification and validation.

Design Qualification (DQ) must establish that facilities, equipment and systems meet approved user requirements and applicable GMP expectations. A risk-based approach should guide the qualification of facilities, equipment, utilities and automated systems.

The design must also address GMP-compliant layouts, personnel and material flows, contamination control, HVAC, utilities and equipment selection. This requires early involvement of Process Engineering, Manufacturing, Quality Assurance, Validation, Mechanical, Electrical, Instrumentation and Automation, and HSE teams.

I strongly recommend establishing two distinct project milestones: Mechanical Completion and GMP Readiness. Clearly defined deliverables for both help coordinate commissioning, qualification and validation activities and minimise delays before commercial manufacturing.

An Example from My Experience

During an earlier pharmaceutical manufacturing project, engineering and validation requirements were integrated from conceptual design onwards.

A VMP established the qualification strategy, documentation and acceptance criteria, covering Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ) for applicable equipment and systems. This included HVAC qualification and cleanroom validation against the required room classifications.

Cross-functional teams regularly reviewed layouts, P&IDs, equipment specifications, utilities and automation requirements throughout execution.

This approach supported mechanical completion, HVAC validation and the qualification of the relevant building management and automation systems, establishing GMP readiness for the manufacturing team to initiate process validation with cross-functional participation.

The facility was subsequently commissioned for commercial manufacturing. The key lesson is that GMP readiness cannot be achieved through documentation alone at the end of construction. It must be engineered into the facility from the beginning.

Q5. When planning a brownfield expansion or a new facility, how should SMEs evaluate existing infrastructure, automation requirements and future digital integration to make sound long-term investment decisions?

Before choosing between brownfield expansion and greenfield development, pharmaceutical SMEs must assess whether the proposed investment will remain technically, commercially and regulatorily viable over the next 10–15 years.

For brownfield projects, this begins with a thorough assessment of existing buildings, utility capacities, equipment suitability and the ability of current GMP systems to support future manufacturing requirements. Infrastructure limitations and compliance gaps must be identified before committing capital.

Automation requirements should be evaluated across manufacturing processes, equipment, utilities, and solvent and chemical handling systems. The objective is to identify what must be automated from the beginning and what can be introduced progressively.

Future digital integration must also be considered during initial engineering. Equipment control systems and communication infrastructure should accommodate technological advancements without requiring extensive modifications later.

A phased investment strategy allows SMEs to prioritise GMP-compliant infrastructure, energy-efficient utilities, instrumentation, automation and digital connectivity in line with business growth.

Smart investment does not mean installing the most advanced technology from the beginning. It means establishing the right engineering and digital foundation today, with the flexibility to upgrade as manufacturing requirements evolve.

About the Guest | Mr. Rajesh Hedaoo

Mr. Rajesh Hedaoo is Managing Director of Gusto Total Solutions Pvt. Ltd., with over four decades of experience in pharmaceutical manufacturing, process engineering and facility development. His career includes leadership roles at Cipla, Wockhardt, Reliance Life Sciences and FDC.

Having worked across more than 100 therapeutic products and led over 10 USFDA inspections, he brings extensive experience in pharmaceutical engineering, manufacturing operations and regulatory compliance.

Disclaimer:

The views and opinions expressed in this editorial are those of the guest and are based on his professional experience. They do not necessarily reflect the views of Hello Pharma. The content is intended for industry knowledge-sharing and should not be construed as specific technical, engineering or regulatory advice.